Last reviewed · How we verify
NCT05700344: SOGUG
SOGUG-AVELUMAB_RWD
trial testing Avelumab in Metastatic Urothelial Carcinoma in 125 participants. Completed in 2 November 2023.
31 July 2023
Quick facts
| Lead sponsor | Spanish Oncology Genito-Urinary Group |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 125 |
| Start date | 5 September 2022 |
| Primary completion | 31 July 2023 |
| Estimated completion | 2 November 2023 |
| Sites | 22 locations across Spain |
Drugs / interventions tested
- Avelumab (avelumab) — full drug profile →
Conditions studied
- Metastatic Urothelial Carcinoma — all drugs for Metastatic Urothelial Carcinoma →
Sponsor
Spanish Oncology Genito-Urinary Group — full company profile →
Who can join
Adults 18 to 120, any sex, with Metastatic Urothelial Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study goal is to evaluate the effectiveness in clinical practice of Avelumab as first line maintenance therapy in patients with locally advanced or metastatic Urothelial Carcinoma, who have not progressed after first line platinum-based treatment. Study is performed at national hospitals from approximately 22 different sites and expecting to recruit 120 patients. Patients understanding the nature of the study by providing their informed consent prior to participation. * Patients of both sexes diagnosed with locally advanced or metastatic Urothelial Carcinoma, stage IV disease before first line with carboplatin/cisplatin-based chemotherapy. No disease progression after four-six cycles of ChT according to the Response Evaluation Criteria in Solid Tumor with a treatment free interval of 4-10 weeks before Avelumab initiation date. * Patients who started Avelumab as maintenance therapy in first line after 21/Jan./2021 and before 27/Apr./2022 (both dates included).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05700344
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Avelumab
Trials testing the same drug.
- NCT06939036 — Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 ) · Phase 1, PHASE2 · terminated
- NCT05687721 — Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer · Phase 1, PHASE2 · withdrawn
- NCT06518564 — Avelumab and M1774 in ARID1A-mutated Endometrial Cancer · Phase 2 · recruiting
- NCT06424717 — Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L · Phase 2 · withdrawn
- NCT06302426 — Trial of INI-4001 in Patients With Advanced Solid Tumours · Phase 1 · recruiting
Other recruiting trials for Metastatic Urothelial Carcinoma
Currently open trials in the same condition.
- NCT07492628 — Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma · Phase 1 · recruiting
- NCT07221942 — Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma · Phase 2 · recruiting
- NCT07390617 — A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma · recruiting
- NCT06524544 — A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of · Phase 3 · recruiting
- NCT06862219 — A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer · Phase 4 · recruiting
Other Spanish Oncology Genito-Urinary Group trials
Trials by the same sponsor.
- NCT07354282 — Real World Evidence of Tivozanib as First-line Treatment for Metastatic Clear Cell Renal Cell Carcinoma · completed
- NCT04602078 — Study of Atezolizumab Combined With Split-dose Gemcitabine Plus Cisplatin in Urothelial Carcinoma · Phase 2 · completed
- NCT04578132 — Description of the Population With Genitourinary Tumors and COVID-19 · completed
- NCT04134390 — Study of Cabozantinib Efficacy, Safety and Tolerability in Metastatic Renal Carcinoma in Aged Fragile Patients: CABOMAYO · Phase 2 · completed
- NCT04510688 — Spanish Real-World Evidence Cabozantinib · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05700344 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Spanish Oncology Genito-Urinary Group
- Last refreshed: 29 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05700344.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing